Lisinopril
Identification
- Name
- Lisinopril
- Accession Number
- DB00722 (APRD00560)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
- Structure
- Synonyms
- (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
- [N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
- Lisinopril
- Lisinopril anhydrous
- Lisinoprilum
- Product Ingredients
Ingredient UNII CAS InChI Key Lisinopril dihydrate E7199S1YWR 83915-83-7 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Lisinopril Tablet 10 mg Oral Actavis Pharma Company 2007-10-17 Not applicable Canada Act Lisinopril Tablet 5 mg Oral Actavis Pharma Company 2007-10-17 Not applicable Canada Act Lisinopril Tablet 20 mg Oral Actavis Pharma Company 2007-10-17 Not applicable Canada Lisinopril Tablet 20 mg Oral Cobalt Laboratories Not applicable Not applicable Canada Lisinopril Tablet 10 mg Oral Sorres Pharma Inc 2009-06-22 2014-06-20 Canada Lisinopril Tablet 5 mg Oral Sivem Pharmaceuticals Ulc 2012-06-11 Not applicable Canada Lisinopril Tablet 40 mg Oral Sivem Pharmaceuticals Ulc Not applicable Not applicable Canada Lisinopril Tablet 10 mg Oral Meliapharm Inc 2008-03-12 2014-06-25 Canada Lisinopril Tablet 20 mg Oral Sivem Pharmaceuticals Ulc 2012-06-11 Not applicable Canada Lisinopril Tablet 10 mg Oral Cobalt Laboratories Not applicable Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-lisinopril Tablet (type P) - 10mg Tablet 10 mg Oral Apotex Corporation 1996-10-30 2001-08-02 Canada Apo-lisinopril Tablet (type P) - 20mg Tablet 20 mg Oral Apotex Corporation 1996-10-30 2001-08-02 Canada Apo-lisinopril Tablet (type P) - 40mg Tablet 40 mg Oral Apotex Corporation 1996-12-30 2001-08-02 Canada Apo-lisinopril Tablet (type P) - 5mg Tablet 5 mg Oral Apotex Corporation 1996-10-30 2001-08-02 Canada Apo-lisinopril Tablet 10 mg Tablet 10 mg Oral Apotex Corporation 1996-10-30 Not applicable Canada Apo-lisinopril Tablet 20 mg Tablet 20 mg Oral Apotex Corporation 1996-10-30 Not applicable Canada Apo-lisinopril Tablet 40 mg Tablet 40 mg Oral Apotex Corporation 1996-10-30 Not applicable Canada Apo-lisinopril Tablet 5 mg Tablet 5 mg Oral Apotex Corporation 1996-10-30 Not applicable Canada Auro-lisinopril Tablet 5 mg Oral Auro Pharma Inc 2013-02-12 Not applicable Canada Auro-lisinopril Tablet 20 mg Oral Auro Pharma Inc 2013-02-12 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Apo-lisinopril/hctz Lisinopril (10 mg) + Hydrochlorothiazide (12.5 mg) Tablet Oral Apotex Corporation 2007-09-05 Not applicable Canada Apo-lisinopril/hctz Lisinopril (20 mg) + Hydrochlorothiazide (25 mg) Tablet Oral Apotex Corporation 2007-11-21 Not applicable Canada Apo-lisinopril/hctz Lisinopril (20 mg) + Hydrochlorothiazide (12.5 mg) Tablet Oral Apotex Corporation 2007-11-21 Not applicable Canada Ava-lisinopril Hct Lisinopril (20 mg) + Hydrochlorothiazide (25 mg) Tablet Oral Avanstra Inc 2011-08-18 2014-08-21 Canada Ava-lisinopril Hct Lisinopril (20 mg) + Hydrochlorothiazide (12.5 mg) Tablet Oral Avanstra Inc 2011-08-18 2014-08-21 Canada Ava-lisinopril Hct Lisinopril (10 mg) + Hydrochlorothiazide (12.5 mg) Tablet Oral Avanstra Inc 2011-08-18 2014-08-21 Canada Lisinopril and HCTZ Lisinopril (20 mg/1) + Hydrochlorothiazide (25 mg/1) Tablet Oral Northwind Pharmaceuticals 2014-07-10 Not applicable US Lisinopril and hydrochlorothiazide Lisinopril (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Remedy Repack 2013-07-05 2017-08-10 US Lisinopril and Hydrochlorothiazide Lisinopril (20 mg/1) + Hydrochlorothiazide (25 mg/1) Tablet Oral A S Medication Solutions 2006-04-10 2017-06-20 US Lisinopril and Hydrochlorothiazide Lisinopril (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Aphena Pharma Solutions Tennessee, Inc. 2013-06-18 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Lytensopril Lisinopril + L-Arginine Kit Physician Therapeutics Llc 2011-07-07 Not applicable US Lytensopril-90 Lisinopril + L-Arginine Kit Physician Therapeutics Llc 2011-07-07 2016-10-13 US - International/Other Brands
- Acebitor (GlaxoSmithKline) / Acemin (AstraZeneca) / Acerbon (AstraZeneca) / Acinopril (sanofi-aventis) / Bellisin (Ranbaxy) / Biopril (Biochem) / Dapril (Medochemie) / Fibsol (Sigma) / Fisopril (Sanofi-Aventis) / Hipril (Micro Labs) / Linopril (Klinger (Brazil)) / Lisipril (Hexal (Czech Republic), Orion (Finland)) / Noperten (Dexa (Indonesia)) / Presiten (Magnachem) / Ranolip (Ranbaxy) / Ranopril (Ranbaxy) / Rantex (Biotech) / Sinopren (Ranbaxy) / Sinopril (Eczacibasi (Russia)) / Tensopril (Merck)
- Categories
- UNII
- 7Q3P4BS2FD
- CAS number
- 76547-98-3
- Weight
- Average: 405.4879
Monoisotopic: 405.226371117 - Chemical Formula
- C21H31N3O5
- InChI Key
- RLAWWYSOJDYHDC-BZSNNMDCSA-N
- InChI
- InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
- IUPAC Name
- (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- NCCCC[[email protected]](N[[email protected]@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[[email protected]]1C(O)=O
Pharmacology
- Indication
For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.
- Structured Indications
- Pharmacodynamics
Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.
- Mechanism of action
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Target Actions Organism AAngiotensin-converting enzyme inhibitorHuman - Absorption
Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food
- Volume of distribution
- Not Available
- Protein binding
Lisinopril does not appear to be bound to serum proteins other than ACE.
- Metabolism
Does not undergo metabolism, excreted unchanged in urine.
- Route of elimination
Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.
- Half life
Effective half life of accumulation following multiple dosing is 12 hours.
- Clearance
- 10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]
- Toxicity
Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD50= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Lisinopril Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisinopril. Investigational 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lisinopril. Experimental Abacavir The serum concentration of Abacavir can be decreased when it is combined with Lisinopril. Approved, Investigational Acebutolol Lisinopril may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Lisinopril. Approved, Investigational Acemetacin The therapeutic efficacy of Lisinopril can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetylsalicylic acid The therapeutic efficacy of Lisinopril can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Lisinopril. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Lisinopril. Approved, Withdrawn Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril. Approved Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Lisinopril. Approved, Investigational Aliskiren Aliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Lisinopril. Approved, Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Lisinopril. Approved Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Lisinopril. Experimental Alogliptin The risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril. Approved Aloxiprin The therapeutic efficacy of Lisinopril can be decreased when used in combination with Aloxiprin. Experimental Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Lisinopril. Approved, Illicit, Investigational Alprenolol Lisinopril may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Ambrisentan Lisinopril may increase the hypotensive activities of Ambrisentan. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lisinopril. Experimental, Investigational Amifostine Lisinopril may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride Amiloride may increase the hyperkalemic activities of Lisinopril. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Lisinopril. Illicit, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Lisinopril. Approved Aminosalicylic Acid The therapeutic efficacy of Lisinopril can be decreased when used in combination with Aminosalicylic Acid. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Lisinopril. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Lisinopril. Approved Amlodipine Amlodipine may increase the hypotensive activities of Lisinopril. Approved Amobarbital Amobarbital may increase the hypotensive activities of Lisinopril. Approved, Illicit Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Lisinopril. Approved Amphetamine Amphetamine may increase the hypotensive activities of Lisinopril. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite. Approved Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Lisinopril. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Lisinopril. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Lisinopril. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Lisinopril. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Lisinopril is combined with Apraclonidine. Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Lisinopril. Approved, Investigational Aprotinin Aprotinin may decrease the antihypertensive activities of Lisinopril. Approved, Investigational, Withdrawn Aripiprazole Aripiprazole may increase the hypotensive activities of Lisinopril. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Lisinopril. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lisinopril. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Lisinopril. Approved Atorvastatin The risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril. Approved Avanafil Avanafil may increase the antihypertensive activities of Lisinopril. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Lisinopril. Withdrawn Azathioprine The risk or severity of anemia and severe leukopenia can be increased when Lisinopril is combined with Azathioprine. Approved Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Lisinopril. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril. Approved, Investigational Azosemide Azosemide may increase the hypotensive activities of Lisinopril. Investigational Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Lisinopril. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Lisinopril. Experimental Barbital Barbital may increase the hypotensive activities of Lisinopril. Illicit Barnidipine Lisinopril may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Lisinopril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Lisinopril. Experimental Bendroflumethiazide The risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Lisinopril. Approved Benmoxin Benmoxin may increase the hypotensive activities of Lisinopril. Withdrawn Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Lisinopril. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisinopril. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Lisinopril. Approved Bepridil Lisinopril may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Lisinopril. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Lisinopril. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Lisinopril. Experimental Bietaserpine Bietaserpine may increase the hypotensive activities of Lisinopril. Experimental Bimatoprost Lisinopril may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Lisinopril. Approved Boceprevir The serum concentration of Lisinopril can be decreased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Lisinopril. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Lisinopril. Approved, Investigational BQ-123 Lisinopril may increase the hypotensive activities of BQ-123. Investigational Bretylium Lisinopril may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Lisinopril. Approved Brofaromine Brofaromine may increase the hypotensive activities of Lisinopril. Experimental Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Lisinopril. Approved Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Lisinopril. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Lisinopril. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Lisinopril. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Lisinopril. Experimental Bumetanide Bumetanide may increase the hypotensive activities of Lisinopril. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lisinopril. Approved, Investigational Bupranolol Lisinopril may increase the hypotensive activities of Bupranolol. Approved Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Lisinopril. Approved Cadralazine Cadralazine may increase the hypotensive activities of Lisinopril. Experimental Cafedrine Lisinopril may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisinopril. Approved Candoxatril Candoxatril may increase the hypotensive activities of Lisinopril. Experimental Captopril Lisinopril may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Lisinopril can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The therapeutic efficacy of Lisinopril can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Lisinopril. Approved, Investigational Caroxazone Caroxazone may increase the hypotensive activities of Lisinopril. Withdrawn Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Lisinopril. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the hypotensive activities of Lisinopril. Approved Carvedilol Lisinopril may increase the hypotensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Lisinopril. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Lisinopril. Approved, Investigational Celiprolol Lisinopril may increase the hypotensive activities of Celiprolol. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Lisinopril. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of hypotension can be increased when Chlorothiazide is combined with Lisinopril. Approved, Vet Approved Chlorotrianisene The serum concentration of Chlorotrianisene can be decreased when it is combined with Lisinopril. Investigational, Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lisinopril. Approved, Investigational, Vet Approved Chlorthalidone The risk or severity of hypotension can be increased when Chlorthalidone is combined with Lisinopril. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisinopril. Approved Cicletanine Lisinopril may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Lisinopril may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Lisinopril. Approved, Investigational Ciprofloxacin The risk or severity of ventricular arrhythmias can be increased when Lisinopril is combined with Ciprofloxacin. Approved, Investigational Clarithromycin The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril. Approved Clevidipine The risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Lisinopril. Approved, Investigational Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Lisinopril. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Lisinopril. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Lisinopril. Approved Cloranolol Lisinopril may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Lisinopril. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Lisinopril. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Lisinopril. Approved Cryptenamine Lisinopril may increase the hypotensive activities of Cryptenamine. Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Lisinopril. Approved, Investigational Cyclobenzaprine The serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril. Approved Cyclopenthiazide The risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Lisinopril. Experimental Cyclophosphamide The risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Lisinopril. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Lisinopril. Approved Dapagliflozin The risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Lisinopril. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Lisinopril. Approved, Investigational Delapril Lisinopril may increase the hypotensive activities of Delapril. Experimental Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Lisinopril. Approved Dersalazine The therapeutic efficacy of Lisinopril can be decreased when used in combination with Dersalazine. Investigational Deserpidine Lisinopril may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Lisinopril. Approved Desipramine The serum concentration of Desipramine can be increased when it is combined with Lisinopril. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Lisinopril. Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Lisinopril. Experimental Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Lisinopril. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide. Approved, Investigational Dienestrol The serum concentration of Dienestrol can be decreased when it is combined with Lisinopril. Approved, Investigational Diethylnorspermine Lisinopril may increase the hypotensive activities of Diethylnorspermine. Investigational Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Lisinopril. Experimental Diflunisal The therapeutic efficacy of Lisinopril can be decreased when used in combination with Diflunisal. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Lisinopril. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Lisinopril. Approved, Investigational Dihydroergotamine The serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril. Approved, Investigational Diltiazem The metabolism of Diltiazem can be decreased when combined with Lisinopril. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab. Approved, Investigational Dipyridamole The risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole. Approved Dorzolamide Lisinopril may increase the hypotensive activities of Dorzolamide. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Lisinopril. Approved Doxazosin Doxazosin may increase the hypotensive activities of Lisinopril. Approved Doxepin The serum concentration of Doxepin can be increased when it is combined with Lisinopril. Approved, Investigational Drospirenone Lisinopril may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Lisinopril. Withdrawn Duloxetine Lisinopril may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Lisinopril. Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Lisinopril. Approved E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Lisinopril. Investigational Efonidipine Lisinopril may increase the hypotensive activities of Efonidipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Enalaprilat Lisinopril may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Lisinopril. Experimental Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril. Approved, Investigational Epanolol Lisinopril may increase the hypotensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Lisinopril. Approved Epitizide The risk or severity of hypotension can be increased when Epitizide is combined with Lisinopril. Experimental Eplerenone Eplerenone may increase the hyperkalemic activities of Lisinopril. Approved Epoprostenol Lisinopril may increase the hypotensive activities of Epoprostenol. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril. Approved Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril. Approved Ergonovine The serum concentration of Ergonovine can be increased when it is combined with Lisinopril. Approved Ergotamine The serum concentration of Ergotamine can be increased when it is combined with Lisinopril. Approved Esmirtazapine The serum concentration of Esmirtazapine can be increased when it is combined with Lisinopril. Investigational Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril. Approved Estradiol The serum concentration of Estradiol can be decreased when it is combined with Lisinopril. Approved, Investigational, Vet Approved Estramustine The serum concentration of Estramustine can be decreased when it is combined with Lisinopril. Approved, Investigational Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Lisinopril. Approved Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril. Approved Etacrynic acid Etacrynic acid may increase the hypotensive activities of Lisinopril. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Lisinopril. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Lisinopril. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lisinopril. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Lisinopril. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Lisinopril. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Lisinopril. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lisinopril. Approved, Investigational Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Lisinopril. Approved Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Lisinopril. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Lisinopril. Experimental Felodipine Lisinopril may increase the hypotensive activities of Felodipine. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Lisinopril. Approved Fenoldopam Lisinopril may increase the hypotensive activities of Fenoldopam. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Lisinopril. Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Lisinopril. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Lisinopril. Experimental Ferulic acid Lisinopril may increase the hypotensive activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Lisinopril. Approved, Investigational Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Lisinopril. Approved, Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Lisinopril. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Lisinopril. Experimental Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lisinopril. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril. Experimental Fosinopril Fosinopril may increase the hypotensive activities of Lisinopril. Approved Furazolidone Furazolidone may increase the hypotensive activities of Lisinopril. Approved, Investigational, Vet Approved Furosemide Furosemide may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Garlic The serum concentration of Lisinopril can be decreased when it is combined with Garlic. Approved Guacetisal The therapeutic efficacy of Lisinopril can be decreased when used in combination with Guacetisal. Experimental Guanabenz Guanabenz may increase the hypotensive activities of Lisinopril. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Lisinopril. Approved Guanazodine Lisinopril may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Lisinopril may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Lisinopril. Approved, Investigational Guanoclor Lisinopril may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Lisinopril may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Lisinopril may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Lisinopril. Experimental Hemoglobin crosfumaril The therapeutic efficacy of Lisinopril can be decreased when used in combination with Hemoglobin crosfumaril. Experimental Heparin The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Heparin. Approved, Investigational Hexamethonium Lisinopril may increase the hypotensive activities of Hexamethonium. Experimental Hexestrol The serum concentration of Hexestrol can be decreased when it is combined with Lisinopril. Withdrawn Hexobarbital Hexobarbital may increase the hypotensive activities of Lisinopril. Approved Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Lisinopril. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Lisinopril. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Lisinopril. Approved Hydrochlorothiazide The risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Lisinopril. Approved, Vet Approved Hydroflumethiazide The risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Lisinopril. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Lisinopril. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Lisinopril. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Lisinopril. Approved, Investigational Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Lisinopril. Approved, Investigational Imidapril Lisinopril may increase the hypotensive activities of Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Lisinopril. Experimental Imipramine The serum concentration of Imipramine can be increased when it is combined with Lisinopril. Approved Indapamide The risk or severity of hypotension can be increased when Indapamide is combined with Lisinopril. Approved Indenolol Lisinopril may increase the hypotensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Lisinopril. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Lisinopril. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Lisinopril. Withdrawn Iprindole The serum concentration of Iprindole can be increased when it is combined with Lisinopril. Experimental Iproclozide Iproclozide may increase the hypotensive activities of Lisinopril. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Lisinopril. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril. Approved, Investigational Iron Iron can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran The risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran. Approved, Vet Approved Isocarboxazid Isocarboxazid may increase the hypotensive activities of Lisinopril. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Lisinopril. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate. Approved Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Lisinopril. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Lisinopril. Approved, Investigational Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Lisinopril. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Lisinopril. Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisinopril. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Lisinopril. Approved Labetalol Labetalol may increase the hypotensive activities of Lisinopril. Approved Lacidipine Lisinopril may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanthanum carbonate The serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate. Approved Latanoprost Latanoprost may increase the hypotensive activities of Lisinopril. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Lisinopril. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Lisinopril. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lisinopril. Approved, Investigational Levodopa Lisinopril may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Lisinopril. Approved, Investigational Linagliptin The risk or severity of adverse effects can be increased when Linagliptin is combined with Lisinopril. Approved Linsidomine Lisinopril may increase the hypotensive activities of Linsidomine. Experimental Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Lisinopril. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Lisinopril. Approved Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Lisinopril. Experimental Lofexidine Lisinopril may increase the hypotensive activities of Lofexidine. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Lisinopril. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Lisinopril. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisinopril. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lisinopril. Approved, Investigational Macitentan Lisinopril may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisinopril. Approved Manidipine Lisinopril may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Lisinopril. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Lisinopril. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Lisinopril. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lisinopril. Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Lisinopril. Approved, Vet Approved Mesalazine The therapeutic efficacy of Lisinopril can be decreased when used in combination with Mesalazine. Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Lisinopril. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril. Approved, Investigational, Withdrawn Methallenestril The serum concentration of Methallenestril can be decreased when it is combined with Lisinopril. Experimental Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Lisinopril. Approved Methohexital Methohexital may increase the hypotensive activities of Lisinopril. Approved Methoserpidine Lisinopril may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The risk or severity of hypotension can be increased when Methyclothiazide is combined with Lisinopril. Approved Methyl salicylate The therapeutic efficacy of Lisinopril can be decreased when used in combination with Methyl salicylate. Approved, Vet Approved Methyldopa Lisinopril may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Lisinopril. Approved, Investigational Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Lisinopril. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Lisinopril. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Lisinopril. Approved Metipranolol Lisinopril may increase the hypotensive activities of Metipranolol. Approved Metolazone The risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril. Approved Metoprolol Metoprolol may increase the hypotensive activities of Lisinopril. Approved, Investigational Metyrosine Lisinopril may increase the hypotensive activities of Metyrosine. Approved Mibefradil Lisinopril may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midazolam The serum concentration of Midazolam can be increased when it is combined with Lisinopril. Approved, Illicit Minaprine Minaprine may increase the hypotensive activities of Lisinopril. Approved Minoxidil Minoxidil may increase the hypotensive activities of Lisinopril. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Lisinopril. Investigational Mirtazapine The serum concentration of Mirtazapine can be increased when it is combined with Lisinopril. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Lisinopril. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Lisinopril. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Lisinopril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Lisinopril. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Lisinopril. Approved, Investigational Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Lisinopril. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Lisinopril. Approved, Investigational Muzolimine Lisinopril may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisinopril. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril. Approved Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Lisinopril. Approved, Investigational Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril. Approved Nadolol Lisinopril may increase the hypotensive activities of Nadolol. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Lisinopril. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Lisinopril. Approved Naftopidil Lisinopril may increase the hypotensive activities of Naftopidil. Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Lisinopril. Approved, Vet Approved Nebivolol Lisinopril may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Lisinopril. Approved, Withdrawn Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Lisinopril. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Lisinopril is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Lisinopril. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Lisinopril. Approved, Investigational Nicorandil Nicorandil may increase the vasodilatory activities of Lisinopril. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine. Approved Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Lisinopril. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisinopril. Approved Niguldipine Lisinopril may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Lisinopril may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Lisinopril. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Lisinopril. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Lisinopril. Approved Nitrendipine Lisinopril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lisinopril. Approved Nitroaspirin The therapeutic efficacy of Lisinopril can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Lisinopril. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Lisinopril. Approved, Investigational Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Lisinopril. Approved Obinutuzumab Lisinopril may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Lisinopril. Withdrawn Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Lisinopril. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Lisinopril. Approved Omapatrilat Lisinopril may increase the hypotensive activities of Omapatrilat. Investigational Opipramol The serum concentration of Opipramol can be increased when it is combined with Lisinopril. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Lisinopril. Vet Approved Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril. Approved Oxprenolol Lisinopril may increase the hypotensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisinopril. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lisinopril. Approved, Vet Approved Papaverine The risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine. Approved, Investigational Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Lisinopril. Approved Pargyline Pargyline may increase the hypotensive activities of Lisinopril. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Lisinopril. Approved, Investigational Patent Blue The therapeutic efficacy of Lisinopril can be decreased when used in combination with Patent Blue. Approved Penbutolol Lisinopril may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentobarbital Pentobarbital may increase the hypotensive activities of Lisinopril. Approved, Investigational, Vet Approved Pentolinium Lisinopril may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Lisinopril. Approved, Investigational Perindopril Lisinopril may increase the hypotensive activities of Perindopril. Approved Pethidine The risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Lisinopril. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Lisinopril. Withdrawn Phenobarbital Phenobarbital may increase the hypotensive activities of Lisinopril. Approved, Investigational Phenoxybenzamine Lisinopril may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Lisinopril. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Lisinopril. Approved Phenyl aminosalicylate The therapeutic efficacy of Lisinopril can be decreased when used in combination with Phenyl aminosalicylate. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisinopril. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisinopril. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Lisinopril. Approved Pindolol Lisinopril may increase the hypotensive activities of Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril. Approved, Investigational Piretanide Piretanide may increase the hypotensive activities of Lisinopril. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisinopril. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Lisinopril. Approved Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Lisinopril. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Lisinopril. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Lisinopril. Withdrawn Platelet Activating Factor Lisinopril may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide The risk or severity of hypotension can be increased when Polythiazide is combined with Lisinopril. Approved Potassium Potassium may increase the hyperkalemic activities of Lisinopril. Approved, Investigational Potassium bicarbonate Potassium bicarbonate may increase the hyperkalemic activities of Lisinopril. Approved Potassium Chloride Potassium Chloride may increase the hyperkalemic activities of Lisinopril. Approved, Withdrawn Potassium Citrate Potassium Citrate may increase the hyperkalemic activities of Lisinopril. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Lisinopril. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Lisinopril. Experimental, Investigational Prazosin Prazosin may increase the hypotensive activities of Lisinopril. Approved Pregabalin The risk or severity of angioedema can be increased when Lisinopril is combined with Pregabalin. Approved, Illicit, Investigational Primidone Primidone may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Lisinopril. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Lisinopril. Experimental Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Lisinopril. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Lisinopril. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Lisinopril. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Lisinopril. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Lisinopril. Experimental Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Lisinopril. Approved PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Lisinopril. Investigational Quetiapine The risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine. Approved Quinapril Lisinopril may increase the hypotensive activities of Quinapril. Approved, Investigational Quinethazone The risk or severity of hypotension can be increased when Quinethazone is combined with Lisinopril. Approved Quinine Quinine may increase the hypotensive activities of Lisinopril. Approved Ramipril Ramipril may increase the hypotensive activities of Lisinopril. Approved Rasagiline Rasagiline may increase the hypotensive activities of Lisinopril. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Lisinopril. Approved Remikiren Remikiren may increase the hypotensive activities of Lisinopril. Approved Rescinnamine Lisinopril may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Lisinopril. Approved, Investigational Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Lisinopril. Approved, Experimental, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Lisinopril. Approved, Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Lisinopril. Approved Risperidone Lisinopril may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Lisinopril may increase the hypotensive activities of Rituximab. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Lisinopril. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lisinopril. Approved Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Lisinopril. Approved Sacubitril The risk or severity of angioedema can be increased when Lisinopril is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Lisinopril. Withdrawn Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisinopril. Approved Salicylic acid The therapeutic efficacy of Lisinopril can be decreased when used in combination with Salicylic acid. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Lisinopril. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Lisinopril. Investigational Saxagliptin The risk or severity of adverse effects can be increased when Saxagliptin is combined with Lisinopril. Approved Secobarbital Secobarbital may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Lisinopril. Approved, Investigational, Vet Approved Selexipag Lisinopril may increase the hypotensive activities of Selexipag. Approved Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Lisinopril. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Lisinopril. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Lisinopril. Investigational Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lisinopril. Approved, Vet Approved Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Lisinopril. Approved, Investigational Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Lisinopril. Approved Sirolimus The risk or severity of angioedema can be increased when Sirolimus is combined with Lisinopril. Approved, Investigational Sitagliptin The risk or severity of adverse effects can be increased when Sitagliptin is combined with Lisinopril. Approved, Investigational Sitaxentan Lisinopril may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium aurothiomalate The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Lisinopril is combined with Sodium aurothiomalate. Approved, Investigational Sodium phosphate Lisinopril may increase the nephrotoxic activities of Sodium phosphate. Approved Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril. Approved Spirapril Lisinopril may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Lisinopril. Investigational St. John's Wort The metabolism of Lisinopril can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Lisinopril. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Lisinopril. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lisinopril. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Lisinopril. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Lisinopril. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Lisinopril. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lisinopril. Approved Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Lisinopril. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Lisinopril. Approved, Investigational Talinolol Lisinopril may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Lisinopril. Approved, Investigational Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisinopril. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril. Approved, Investigational Temocapril Lisinopril may increase the hypotensive activities of Temocapril. Experimental, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus. Approved Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Lisinopril. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Lisinopril. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Lisinopril. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisinopril. Approved Terlipressin Lisinopril may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Lisinopril may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Lisinopril. Approved, Investigational, Withdrawn Theodrenaline Lisinopril may increase the hypotensive activities of Theodrenaline. Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Lisinopril. Approved Thiamylal Thiamylal may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Lisinopril. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Lisinopril. Approved, Withdrawn Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Lisinopril. Approved, Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisinopril. Approved Tibolone Lisinopril may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Lisinopril may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Timolol may increase the hypotensive activities of Lisinopril. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Lisinopril. Investigational Tipranavir The serum concentration of Lisinopril can be decreased when it is combined with Tipranavir. Approved, Investigational Tizanidine Tizanidine may increase the hypotensive activities of Lisinopril. Approved, Investigational Tolazoline Lisinopril may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Lisinopril. Approved, Withdrawn Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisinopril. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Lisinopril. Approved Tolonidine Lisinopril may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Lisinopril. Approved Tolvaptan Tolvaptan may increase the hyperkalemic activities of Lisinopril. Approved Torasemide Torasemide may increase the hypotensive activities of Lisinopril. Approved Trandolapril Trandolapril may increase the hypotensive activities of Lisinopril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Lisinopril. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Lisinopril. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Lisinopril. Approved Treprostinil Treprostinil may increase the hypotensive activities of Lisinopril. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Lisinopril. Approved, Investigational, Nutraceutical Triamterene Triamterene may increase the hyperkalemic activities of Lisinopril. Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Lisinopril. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Lisinopril. Experimental Trichlormethiazide The risk or severity of hypotension can be increased when Trichlormethiazide is combined with Lisinopril. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Lisinopril. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Lisinopril. Approved, Investigational Trimethoprim Trimethoprim may increase the hyperkalemic activities of Lisinopril. Approved, Vet Approved Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Lisinopril. Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Lisinopril. Investigational Trolamine salicylate The therapeutic efficacy of Lisinopril can be decreased when used in combination with Trolamine salicylate. Approved Udenafil Udenafil may increase the antihypertensive activities of Lisinopril. Approved, Investigational Unoprostone Lisinopril may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Lisinopril. Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Lisinopril. Approved, Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Lisinopril. Approved, Investigational Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Lisinopril. Approved Verapamil The metabolism of Verapamil can be decreased when combined with Lisinopril. Approved Vildagliptin The risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril. Approved, Investigational Vincamine Lisinopril may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Lisinopril may increase the hypotensive activities of Vinpocetine. Investigational Xipamide Lisinopril may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Lisinopril may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Lisinopril. Approved, Investigational, Vet Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril. Approved, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Lisinopril. Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Lisinopril. Approved, Investigational, Withdrawn Zofenopril Lisinopril may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Lisinopril. Withdrawn - Food Interactions
- Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
- High salt intake may attenuate the antihypertensive effect of lisinopril.
- Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
- Take without regard to meals.
References
- Synthesis Reference
Vincenzo Cannata, Valeriano Merli, Stefano Saguatti, "Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril." U.S. Patent US6166217, issued September, 1972.
US6166217- General References
- Abdelmalek MF, Douglas DD: Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Dig Dis Sci. 1997 Apr;42(4):847-50. [PubMed:9125659]
- Hasslacher C: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications. 1996 May-Jun;10(3):136-8. [PubMed:8807458]
- Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009 Sep;32(9):1684-8. doi: 10.2337/dc09-0429. Epub 2009 Jun 5. [PubMed:19502542]
- Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826]
- External Links
- Human Metabolome Database
- HMDB0001938
- KEGG Drug
- D00362
- PubChem Compound
- 5362119
- PubChem Substance
- 46504893
- ChemSpider
- 4514933
- BindingDB
- 50367879
- ChEBI
- 43755
- ChEMBL
- CHEMBL1237
- Therapeutic Targets Database
- DAP000587
- PharmGKB
- PA450242
- HET
- LPR
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Lisinopril
- ATC Codes
- C09AA03 — Lisinopril
- C09AA — ACE inhibitors, plain
- C09A — ACE INHIBITORS, PLAIN
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- C09BB — ACE inhibitors and calcium channel blockers
- C09B — ACE INHIBITORS, COMBINATIONS
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- C09BA — ACE inhibitors and diuretics
- C09B — ACE INHIBITORS, COMBINATIONS
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 24:32.04 — Angiotensin-converting Enzyme Inhibitors
- PDB Entries
- 1j36 / 1o86 / 2c6n / 2x91
- FDA label
- Download (267 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Actavis elizabeth llc
- Apotex inc etobicoke site
- Aurobindo pharma ltd
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Lek pharmaceuticals d d
- Lupin ltd
- Mylan pharmaceuticals inc
- Ranbaxy pharmaceuticals inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Vintage pharmaceuticals llc
- Watson laboratories inc
- West ward pharmaceutical corp
- Wockhardt ltd
- Merck research laboratories div merck co inc
- Astrazeneca uk ltd
- Packagers
- Advanced Pharmaceutical Services Inc.
- Aidarex Pharmacuticals LLC
- Amerisource Health Services Corp.
- Apotex Inc.
- Apotheca Inc.
- A-S Medication Solutions LLC
- AstraZeneca Inc.
- Aurobindo Pharma Ltd.
- Blu Pharmaceuticals LLC
- Bryant Ranch Prepack
- Cardinal Health
- Comprehensive Consultant Services Inc.
- Coupler Enterprises Inc.
- Dept Health Central Pharmacy
- DHHS Program Support Center Supply Service Center
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Eon Labs
- Golden State Medical Supply Inc.
- Greenstone LLC
- Group Health Cooperative
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Innoviant Pharmacy Inc.
- International Laboratories Inc.
- IPR Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Lek Pharmaceuticals Inc.
- Liberty Pharmaceuticals
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mckesson Corp.
- Medvantx Inc.
- Merck & Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neighborcare Repackaging Inc.
- Novartis AG
- Nucare Pharmaceuticals Inc.
- Ohm Laboratories Inc.
- Palmetto Pharmaceuticals Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Professional Co.
- Promex Medical Inc.
- Qualitest
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Remedy Repack
- Resource Optimization and Innovation LLC
- Sandhills Packaging Inc.
- Sandoz
- Southwood Pharmaceuticals
- Stat Rx Usa
- Stat Scripts LLC
- Talbert Medical Management Corp.
- Teva Pharmaceutical Industries Ltd.
- Torpharm Inc.
- Tya Pharmaceuticals
- UDL Laboratories
- Va Cmop Dallas
- Vangard Labs Inc.
- Watson Pharmaceuticals
- West-Ward Pharmaceuticals
- Wockhardt Ltd.
- Dosage forms
Form Route Strength Tablet Oral 40 mg Tablet Oral 5 mg Tablet Oral 10 1/1 Tablet Oral 10 mg/301 Tablet Oral 10 mg/1 Tablet Oral 2.5 mg/1 Tablet Oral 20 mg/1 Tablet Oral 30 mg/1 Tablet Oral 40 mg/1 Tablet Oral 5 mg/1 Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 2.5 mg/1 Tablet, film coated Oral 20 mg/1 Tablet, film coated Oral 30 mg/1 Tablet, film coated Oral 40 mg/1 Tablet, film coated Oral 5 mg/1 Tablet Oral Kit Tablet Oral 10 mg Tablet Oral 2.5 mg Tablet Oral 20 mg Solution Oral 1 mg/mL - Prices
Unit description Cost Unit Prinivil 90 20 mg tablet Bottle 111.71USD bottle Prinzide 30 20-12.5 mg tablet Bottle 45.99USD bottle Prinivil 30 2.5 mg tablet Bottle 22.48USD bottle Lisinopril 100% powder 21.6USD g Zestril 40 mg tablet 2.53USD tablet Zestril 30 mg tablet 2.41USD tablet Prinivil 40 mg tablet 2.23USD tablet Zestoretic 20-25 mg tablet 2.01USD tablet Zestoretic 20-12.5 mg tablet 2.0USD tablet Prinzide 20-25 mg tablet 1.98USD tablet Zestoretic 10-12.5 mg tablet 1.89USD tablet Zestoretic 10-12.5 tablet 1.75USD tablet Lisinopril 30 mg tablet 1.53USD tablet Lisinopril 40 mg tablet 1.44USD tablet Prinzide 20-12.5 mg tablet 1.38USD tablet Prinzide 10-12.5 mg tablet 1.37USD tablet Zestril 20 mg tablet 1.37USD tablet Zestril 10 mg tablet 1.33USD tablet Zestoretic 20-25 tablet 1.28USD tablet Zestril 5 mg tablet 1.28USD tablet Zestoretic 20-12.5 tablet 1.26USD tablet Lisinopril 20 mg tablet 1.09USD tablet Prinivil 20 mg tablet 1.05USD tablet Zestril 2.5 mg tablet 1.04USD tablet Lisinopril 10 mg tablet 1.01USD tablet Prinivil 10 mg tablet 1.01USD tablet Lisinopril 5 mg tablet 0.99USD tablet Prinivil 5 mg tablet 0.96USD tablet Apo-Lisinopril 20 mg Tablet 0.71USD tablet Co Lisinopril 20 mg Tablet 0.71USD tablet Mylan-Lisinopril 20 mg Tablet 0.71USD tablet Novo-Lisinopril (Type P) 20 mg Tablet 0.71USD tablet Novo-Lisinopril (Type Z) 20 mg Tablet 0.71USD tablet Pms-Lisinopril 20 mg Tablet 0.71USD tablet Ran-Lisinopril 20 mg Tablet 0.71USD tablet Ratio-Lisinopril P 20 mg Tablet 0.71USD tablet Ratio-Lisinopril Z 20 mg Tablet 0.71USD tablet Sandoz Lisinopril 20 mg Tablet 0.71USD tablet Lisinopril 2.5 mg tablet 0.65USD tablet Apo-Lisinopril 10 mg Tablet 0.59USD tablet Co Lisinopril 10 mg Tablet 0.59USD tablet Mylan-Lisinopril 10 mg Tablet 0.59USD tablet Novo-Lisinopril (Type P) 10 mg Tablet 0.59USD tablet Novo-Lisinopril (Type Z) 10 mg Tablet 0.59USD tablet Pms-Lisinopril 10 mg Tablet 0.59USD tablet Ran-Lisinopril 10 mg Tablet 0.59USD tablet Ratio-Lisinopril P 10 mg Tablet 0.59USD tablet Ratio-Lisinopril Z 10 mg Tablet 0.59USD tablet Sandoz Lisinopril 10 mg Tablet 0.59USD tablet Apo-Lisinopril 5 mg Tablet 0.49USD tablet Co Lisinopril 5 mg Tablet 0.49USD tablet Mylan-Lisinopril 5 mg Tablet 0.49USD tablet Novo-Lisinopril (Type P) 5 mg Tablet 0.49USD tablet Novo-Lisinopril (Type Z) 5 mg Tablet 0.49USD tablet Pms-Lisinopril 5 mg Tablet 0.49USD tablet Ran-Lisinopril 5 mg Tablet 0.49USD tablet Ratio-Lisinopril P 5 mg Tablet 0.49USD tablet Ratio-Lisinopril Z 5 mg Tablet 0.49USD tablet Sandoz Lisinopril 5 mg Tablet 0.49USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US9463183 No 2015-11-06 2035-11-06 US US9616096 No 2015-11-06 2035-11-06 US US9814751 No 2015-11-06 2035-11-06 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 9.7E+004 mg/L MERCK INDEX (1996) logP -1.01 MERCK INDEX (1996); pH 7 pKa 2.5 (at 25 °C) MERCK INDEX (1996) - Predicted Properties
Property Value Source Water Solubility 0.216 mg/mL ALOGPS logP -1.2 ALOGPS logP -3.1 ChemAxon logS -3.3 ALOGPS pKa (Strongest Acidic) 3.17 ChemAxon pKa (Strongest Basic) 10.21 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 132.96 Å2 ChemAxon Rotatable Bond Count 12 ChemAxon Refractivity 107.37 m3·mol-1 ChemAxon Polarizability 43.5 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.6426 Blood Brain Barrier - 0.8815 Caco-2 permeable - 0.7605 P-glycoprotein substrate Substrate 0.6515 P-glycoprotein inhibitor I Non-inhibitor 0.9512 P-glycoprotein inhibitor II Non-inhibitor 0.969 Renal organic cation transporter Non-inhibitor 0.8574 CYP450 2C9 substrate Non-substrate 0.8793 CYP450 2D6 substrate Non-substrate 0.7622 CYP450 3A4 substrate Non-substrate 0.725 CYP450 1A2 substrate Non-inhibitor 0.8999 CYP450 2C9 inhibitor Non-inhibitor 0.9708 CYP450 2D6 inhibitor Non-inhibitor 0.9653 CYP450 2C19 inhibitor Non-inhibitor 0.8266 CYP450 3A4 inhibitor Non-inhibitor 0.907 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9821 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.9389 Biodegradation Not ready biodegradable 0.6844 Rat acute toxicity 1.8723 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9641 hERG inhibition (predictor II) Non-inhibitor 0.8708
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Benzene and substituted derivatives / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides show 9 more
- Substituents
- Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- dipeptide (CHEBI:43755)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
References
- Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
- Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
- Tellez-Sanz R, Garcia-Fuentes L, Baron C: Calorimetric analysis of lisinopril binding to angiotensin I-converting enzyme. FEBS Lett. 1998 Feb 13;423(1):75-80. [PubMed:9506845]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:00